Surgery Done. Pathological Complete Response.

After everything since November — the diagnosis, the cardiac pause, EC, weekly Taxol, Phesgo, scan after scan — 30 May 2026 was the day we finally got the operation done.

And on 8 June, the pathology report came back with the result we had been hoping for since the first encouraging ultrasound: a pathological complete response (pCR).

---

What surgery involved

The plan had been building for months. By May, the steps looked like this:

• 22 May: Magseed marker inserted (a tiny magnetic seed to guide the surgeon to the right spot)
• 29 May: Sentinel node injection
• 30 May: admission at 06:30 for the main operation

The operation itself was two things on the same day:

1. Therapeutic mammoplasty — removing the area where the cancer had been, but reshaping the breast rather than taking the whole breast (the breast-conserving aim we had discussed with the surgeon back in February)
2. Axillary clearance — removing the lymph nodes from the armpit, which had always been part of the plan because of how extensive the node involvement was at diagnosis

That combination — lumpectomy-style surgery plus a full axillary clearance — is a big day by any measure. But it went ahead as planned.

---

The headline: pCR

Pathology takes a little while. When the report landed on 8 June, the headline was clear:

Pathological complete response.

In plain English: under the microscope, there was no viable invasive breast cancer left in the tissue removed from the breast, and no cancer in any of the 31 lymph nodes examined from the axilla.

The formal scoring puts it simply:

• RCB 0 (Residual Cancer Burden zero — the best category)
• ypT0 ypN0 — no residual tumour in the breast; no involved nodes after treatment

That is the definitive answer chemo and months of imaging could only point towards. Surgery pathology confirmed it.

---

The lymph nodes: zero positive, with a story to tell

0 out of 31 nodes contained cancer.

Four nodes did show signs of regression — essentially scarring and treatment-related change from where cancer had been, not active disease. That fits with what we already knew from scans: the axilla had responded dramatically to chemo long before surgery.

No lymphovascular invasion was seen either — another reassuring line on the report.

---

The one detail worth understanding: the medial margin

Most of the report reads like a victory lap. There is one finding that is worth explaining properly, because the words sound alarming until you know what they mean.

What is a “cancerised lobule”?

Breast tissue is made up of lobules (milk-gland units) and ducts. A cancerised lobule is a small area where a lobule shows abnormal, cancer-associated changes under the microscope.

It is not the same thing as “we found residual invasive cancer.” The main breast specimen — the wide local excision where the tumour bed was — showed no residual invasive carcinoma and no DCIS (pre-invasive disease). That is what drives the pCR call.

A small cancerised lobule was also noted elsewhere in the main specimen. Separately, when the pathologist took an extra shave from the medial (inner) margin — an additional sliver of tissue from that edge — they found a 1.5 mm focus of a cancerised lobule.

Why this is being taken seriously (and why that is good)

Margins matter in breast surgery. The pathologist’s job is to be precise, not optimistic.

The important measurements:

• The focus was 3 mm clear of the actual new cut edge — there was a buffer of normal tissue between it and the margin line
• There was no unequivocal DCIS or invasive malignancy in that margin shave
• Extra immunohistochemistry stains were requested on that block (myoepithelial markers — tests that check whether the normal protective “fence” around the lobule is still intact)

Those stains are a belt-and-braces check. They help the pathologist be certain about what they are seeing. Requesting them is thoroughness, not panic.

How I am reading it

The overall picture is overwhelmingly positive: pCR in the breast, clear nodes, no lymphovascular invasion.

The margin note is a small footnote under active review, not a reversal of the main result. The pCR classification stands. If anything, it reflects how carefully the team is reading every millimetre — which is exactly what you want when the goal has been complete response all along.

---

What pCR means for the road ahead

pCR was always the goal on the treatment roadmap sketch from November — the best possible surgical outcome after neoadjuvant chemo for HER2-positive disease.

It does not mean “finished forever.” Phesgo, radiotherapy, and further HER2-targeted treatment decisions still lie ahead, guided by MDT discussion and what pathology shows overall.

But it does mean something concrete and enormous: the treatment worked. The cancer that was biopsied, scanned, and measured for months is, on the evidence of this surgery, gone from the breast and axilla.

After everything, that is a result worth pausing on.